Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2019

View Archived Issues

Enrollment open in phase II trial of ADU-S100 for head and neck cancer

Resistance can be relative, luckily

Better blood supply for better blood sugar control

Acute liver failure can be monogenic condition

3-Substituted quinolines as RORgammat inverse agonists with improved physicochemical properties

Zealand begins phase I trial of ZP-7570 for short bowel syndrome

Bionomics reports results from phase II exploratory study of BNC-210

First patient dosed in phase I/Ib study of PRGN-3006 UltraCART in AML or MDS

Initiation of pivotal phase III clinical trial of mavorixafor for the treatment of WHIM syndrome

Topline data released from phase IIa study of gemcabene in familial partial lipodystrophy

First data presented for novel small-molecule BTK PET tracer

OTG-005: a candidate for the treatment of resistant Gram-negative bacteria

Dupixent obtains U.S. approval for chronic rhinosinusitis with nasal polyposis

European Commission approves Sixmo to treat opioid dependence

Tinostamustine shows efficacy in first-in-human dose-escalation study in lymphoid lymphomas

ENCORE-LF study of emricasan in NASH does not meet primary endpoint

Hanmi Science patents protein kinase inhibitors

NuCana presents new diphosphate phosphoramidate nucleosides for cancer

BIAL-Portela discloses DBH inhibitors

Esteve Pharmaceuticals describes new analgesics

PRMT5 inhibitors described in Angex Pharmaceutical patent

New phase III study explores use of delamanid to prevent people at high risk from developing MDR-TB

Erytech enrolls first patient in TRYbeCA2 trial of eryaspase in first-line TNBC

Verrica reports promising topline data from phase II study of VP-102 in verruca vulgaris

CBD-based antibiotic vanquishes Gram-positive bugs in early test

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...